Overview
- A peer‑reviewed report in Med says a CD19‑targeted CAR‑T infusion put a 47‑year‑old woman’s autoimmune hemolytic anemia, immune thrombocytopenia, and antiphospholipid syndrome into about 11 months of remission.
- Treated under compassionate use after nine failed therapies and a long hospital stay, she stopped daily blood transfusions within days and saw blood counts return toward normal within weeks.
- Her team used Zorpo‑cel, which reprograms the patient’s T cells to seek B cells that carry the CD19 marker after chemotherapy reduced existing immune cells.
- Doctors reported no major CAR‑T toxicities during follow‑up, though some immune cells stayed low and her liver had intermittent problems with uncertain cause.
- Researchers say the pattern points to an immune reset and urge controlled trials to confirm durability and safety, noting broader use will depend on strong evidence and scalable manufacturing.